Retired NYSE Broker & NASD Trader
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey Man,, Very Good!!!!!!!!!!!
The Agreements with ONPH,, and the NC Pfds issued to Mr K.,, keep any hostile folk away while RGBP gets their ducks lined up for the eventual buy out offer from u-no-who--- gotta keep the SEC happy
Which broker??
E-terd and Fidelity won't let me buy
Yeah,, almost 4 milly traded and high of .003!!!
Something is going on---had a high of .0085 a couple of weeks ago--
I agree--and thanks
Yeah,, me tooo and a bunch of others!!!!
I like butter and salt on my Popcorn!!!
But,, to matters of more importance---A buy-out?? How about late this year or early next year by our friend ONPH---
The recent analyst's report (( INSIDER FINANCIAL)) says that they will have a pps of several hundreds of dollars by year end----
Thank you--
I get a CAT scan of my Aortic Heart Valve done this Friday --they will design and build a new Heart Valve for me from the Scan--insert the valve and a Pacemaker via my Femoral Artery- and VIOLA----talk about 21st century medicine!!!!!
Then it's back to the golf course---RGBP will be buying me a new set of sticks and a new golf cart---
Go-Gold----this is just my opinion---but, I grew a lot of whiskers over the years earning my opinions----
To answer your question, Yes,,, I unequivocally believe that our CEO intends to establish this company , RGBP, to be purchased, as in, bought out by large pharma-----He is getting the necessary corporate ""ducks"" correctly lined up----control is now firmly established,,,transparency is being arranged with the audits of the financials,, going current with the SEC will be the final "duck"---imho.
Does our CEO have someone in mind??? Has our CEO been visiting with a "purpose" with another big pharma??? I would surmise that he is guilty of both---but that, also, is just my opinion.
Cheers, and GLTY
Long and Strong
Item 3.03 Material Modification to Rights of Security Holders.
The issuance of 10,000 shares of Nonconvertible Series NC Preferred Stock to David R. Koos on April 23, 2021 will adversely affect the voting power of holders of common stock and other series of preferred stock of Regen due to the disproportionately high voting rights granted to holders of the Nonconvertible Series NC Preferred Stock.
To the extent that the Nonconvertible Series NC Preferred Stock may have anti-takeover effects, Regen believes that the ability of Regen to issue shares with such voting power will encourage persons seeking to acquire Regen to negotiate directly with the Board of Directors enabling the Board of Directors to consider the proposed transaction in a manner that best serves the stockholders’ interests.
Item 3.03 Material Modification to Rights of Security Holders.
The issuance of 10,000 shares of Nonconvertible Series NC Preferred Stock to David R. Koos on April 23, 2021 will adversely affect the voting power of holders of common stock and other series of preferred stock of Regen due to the disproportionately high voting rights granted to holders of the Nonconvertible Series NC Preferred Stock.
To the extent that the Nonconvertible Series NC Preferred Stock may have anti-takeover effects, Regen believes that the ability of Regen to issue shares with such voting power will encourage persons seeking to acquire Regen to negotiate directly with the Board of Directors enabling the Board of Directors to consider the proposed transaction in a manner that best serves the stockholders’ interests.
HEY___
NICE TO SEE YOU BACK!!!!!!!!!!!!!!!!!!!!!!!!
Site will not open????
This site can’t be reachedarchive.fast-edgar.com took too long to respond.
Try:
Checking the connection
Checking the proxy and the firewall
Running Windows Network Diagnostics
ERR_CONNECTION_TIMED_OUT
https://www.quantiumresearch.co.uk/post/are-regen-biopharma-s-fortunes-about-to-change
Are Regen BioPharma's Fortunes About To Change?
Regen BioPharma inc has had a torrid week, seeing a 78% collapse in share price since the high on April 12th. Could its fortunes be about to change? Price action since the April 12th high has traced out a falling wedge pattern, which is intrinsically bullish and expects a rally to follow a breakout of the pattern to the upside. See figure 1.
Figure 1
Note the contracting volume throughout the development of the wedge, which confirms the formation as corrective and strengthens the case for anticipating a break to the upside. If the breakout materialises, volume should begin to expand as the share price rises to continue confirming.
Price targets can be derived for falling wedges by measuring the base of the wedge and projecting that from the point of breakout. In this case, the method yields an upside target somewhere in the region of $0.0674, to be confirmed more precisely once the breakout occurs.
It should also be observed that the termination of the wedge is coming in proximity to the 78.6% Fibonacci retracement level, which has also historically acted as a barrier to price. Support from this level provides a degree of extrinsic bullish bias, which corroborates the intrinsic bullish bias associated with the pattern. This will be a very interesting chart to watch over the coming days and weeks. The next moves have the potential to be quite dramatic
And ,, also,, ya know, David did not just fall off the turnip truck on the way back to the farm--
Methinks the same---
Current =s more brokerages, more folks , more visibility, more transparency, more fun, more action, and higher pps
I honestly do not think that the audit will take 3 months ,, or 2 months --I think that it was expressly explained on this board by a practicing CPA what is entailed----and the auditors do not start from scratch , they have to have something to audit--as in completed financials , but unaudited-----
I have been around this, our stock market, longer than anyone here, I stated to my family that they were not to touch this freebie investment position---for at least 3 years if I have another one of these heart ""thingies"" that precludes me from a new aortic valve---The VA now has to have their ""due process""--so I am delayed again for another 30 days--
Besides ENZC, this has been a beautiful ride with lots of flipping and trading opportunities,,, besides being a gorgeous, longer term, leave it alone type -------
I have a few mil, freebies now,, at low double zeros and a nice flipping position of a few hundred K for entertainment---isn't that what it is supposed to be ,, at my age??? entertainment --- trying to out think and out maneuver the MMs????
In the old days we got a Pink Sheet and a White Sheet for the unlisted stocks---OTC still did not exist---The stocks listed on the Sheets had last weeks volume, trading range and last sale---a current bid and ask and the MMs phone number------Yeah,, try and make a living off that---just ask Jesse Livermore what he thought of that shit----no wonder he stuck to listed stocks---
Ciao, Art
PS___I don't think it is dilution either---need proof for that--
ciao
SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) On April 7, 2021 Oncology Pharma, Inc. (the "Company") reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments utilizing Regen's proprietary intellectual property pertaining to mRNA.
A Spokesperson for the Company, today expanded on the reasons for obtaining this license stating:
"Pancreatic Cancer is one of the most lethal forms of cancer ranking as the fourth leading cause of cancer deaths in the United States. The median survival duration from diagnosis until death for untreated advanced pancreatic cancer is approximately 3 1/2 months; increasing to about eight months with treatment.
mRNA vaccines have become a promising platform for cancer immunotherapy. The intellectual property which we licensed from Regen encompasses an exciting method of utilizing mRNA to cause changes in the cancer cells which would stimulate the patient's own immune response to battle this deadly disease.
According to the National Cancer Institute more than 1.7 million new cases of pancreatic cancer emerge in the United States per year resulting in 609,604 deaths. The cost of treating pancreatic cancer in the United States is $174 billion per year and growing. These are staggering numbers.
We believe that developing a solid therapy to treat this disease is our mission. We want to help save lives and bring hope where currently little hope exists. We believe our mRNA based pancreatic cancer therapies will prove dynamic and powerful."
The Spokesperson further noted "We are more than a biotechnology company. We believe our shareholders expect us to not only develop therapies that improve lives but to develop therapies that save lives. Knowing what we know about pancreatic cancer, this is a great cornerstone on which to focus our Company's research activities."
NO,, there will be no buy back of common shares by the company-----growth companies and young start ups do not ever do such,,,
Methinks your crystal ball may have flaw--
or a BIG crack
Again, again, and again, market is speaking to us loud and clear and it is not letting up, too much pent up demand for this stock, just too much.
The dip may be over,, but we are only off apenny from the close ---could another penny drop, but maybe not
Nice Flush job today---
sorta like what I posted for yesterday-
It'll be over shortly--
JUST MY 2 CENTS
But we have seen this before----::: After the opening bell, the pps moves up on an imbalance of orders favoring the bid or buy side and then the demand slackens ,, maybe even drys up for several seconds,, the MMs flash drop the pps all the way to the gap, taking out all the stops and then whisks the pps right back up---
If you did not have a bid sitting there ,, well,, you missed it-
Ciao
Precisely!!!!!!!!!!!!!!!!!
This is a Pfd stock----and not meant for flipping,, as in day trading---doesn't have the liquidity---It is designed for institutions and income conscious investors with inflation protection----long term retirement accts--
I have over 30 years exp in the NYSE and NASD-----I never in my entire life time of selling and suggesting investment vehicles recommended a Pfd for a person using a margin or cash acct for trading---
This you buy at as favorable a price as you can and set it aside----eventually the company may pay dividends-----and if you own a mil or so from this pps level---well you can do the math and see the lucrative return on your investment---
Want to trade ---buy the common---lots of liquidity--you can flip million or hundred thousand share trades----
HI--You should be green now--
Resistance2: 0.0295
Pivot Point 0.0039
Methinks we open above the the Pivot Point.....
Moving Averages analysis
Price and moving averages has closed above its Short term moving average. Short term moving average is above its mid-term; and above long term moving averages.
From the relationship between price and moving averages; we can see that: this stock is BULLISH in short-term; and BULLISH in mid-long term.
You should watch it Monday---possible gapper
JBZMY and the rest of the china thingy---made some bank and fled the scene---floridaNY is still hanging around---are you???
You need to take a few and read the DD---just a little of it would answer your ??s
Regen BioPharma Inc (OTCMKTS: RGBP)
Is the new darling of small caps currently making a parabolic run up the charts and quickly establishing itself as a top traded stock in small caps.
Currently under heavy accumulation RGBP traded $50 million in dollar volume on Thursday alone on 3.5 billion shares traded and is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension –
Tesoro went to multi dollars. RGBP is in beast mode right now and is the most talked about small cap stock; a break over $0.0295 and things really start popping here.
Regen and its subsidiary KLS have entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity.
An epitope is the part of an antigen that is recognized by the immune system.
The Company is currently in the process of updating its filings and preparing outstanding 10Q and 10k reports in order to up list to fully reporting otcqb “pink current” tier
Cheers
Here is the link to an interesting read about a similar company that even references ENZC----
I say similar , in that both have patents on life saving medicine that need big pharma to arrange a licensing deal-----
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-parabolic-run-on-kls-oncology-pharma-deal/131542/?amp&__twitter_impression=true
Yes, BB, that is the company--
Very similar to the beginning of ENZC 's breakout---
I am making some decent bank on RGB P and will drain off some and replace my WCVC position---and let it ride as "free" shares---cheers
You wonder if I own ENZC???
Does a monkey climb trees???
or you wonder if I own shares in that upstart, non compliant POS????
Does a bear like honey and shit in the woods???
The way it looks now ,, is that upstart non compliant sub penny is going to run away and hide the banana-----
THIS POST????
IF SO,,, WHY DON'T WE HAVE A LICENSING DEAL????
DON'T WE HAVE THE GOODS???
BillionBux Member Level Friday, 04/09/21 10:13:05 PM
Re: fb454 post# 97499 0
Post #
97529
of 97546
https://s26.q4cdn.com/118709596/files/doc_presentations/2021/03/IMM_Non-Confidential-Deck-Mar-29-2021-FINAL.pdf
That is the link to the immunome power point presentation packet. Note slide #6 and see depiction of needle in haystack on right hand side of slide .
Then refer to:
https://www.accesswire.com/638948/Coronavirus-Targeted-Epitopes-Claimed-in-Enzolytics-Pending-Patent-Applications-are-Verified-as-Fully-Conserved-in-the-UK-Brazil-and-South-African-Variants-of-the-Coronavirus-SARS-COV-2
And this particular paragraph:
“CEO Charles Cotropia said, "The discoveries made by our AI team, and implemented by our research team, are extremely significant. The creation of monoclonal antibodies that target the Achilles' heels of the Coronavirus, which will be present even in mutated strains worldwide, means that a therapeutic may be produced that will have affect throughout the world and for the expected continuous lifecycle of the Coronavirus. These findings have their origin in the critical analysis performed by our AI team, which has used sophisticated computer analysis and years of AI experience to curate the amino acid sequences (which are in the tens of thousands) of each of the over 50,000 Coronavirus isolates now known. From this analysis, our AI team has identified the "GOLDEN NEEDLES" in an enormous HAYSTACK of data. This is a remarkable achievement.“
Coincidence?
PS---
There is a lot of very good and very provoking DD on that (used to be sub penny upstart)----it has a ways to go before it catches up with this Pony--
But,, Methinks I saw similar here a month or so back--
It looks very similar to the beginning of run that we just witnessed here---without the ugly cliff hanging fall into ????? should I say "oblivion"??? come on Charles,, get us a licensing deal--
Yes,, you need to know what you own and why you own it--
But, what you own does not know you own it and doesn't care that you own it--
Therefore ,, beware of what you own and what you do with your ownership--
cheers